Market revenue in 2023 | USD 303.6 million |
Market revenue in 2030 | USD 477.3 million |
Growth rate | 6.7% (CAGR from 2023 to 2030) |
Largest segment | Anti- inflammatories |
Fastest growing segment | Combination therapy |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Anti- inflammatories, Bronchodilators, Combination therapy |
Key market players worldwide | Teva Pharmaceutical Industries Ltd, GSK PLC, Merck & Co Inc, Roche Holding AG, AstraZeneca PLC, Boehringer Ingelheim, Sanofi SA, Koninklijke Philips NV, BD, Corvus Pharmaceuticals Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to asthma therapeutics market will help companies and investors design strategic landscapes.
Anti- inflammatories was the largest segment with a revenue share of 61.99% in 2023. Horizon Databook has segmented the Mexico asthma therapeutics market based on anti- inflammatories, bronchodilators, combination therapy covering the revenue growth of each sub-segment from 2018 to 2030.
Mexico has a high rate of lung diseases. With the rapid growth in the country’s biotechnology & biopharmaceutical industries due to the increasing number of startups & rising investments, the market is anticipated to witness significant growth over the forecast period.
Factors such as unhealthy diets, physical inactivity, and insufficient awareness about lifestyle-induced disorders are responsible for the growing disease burden. According to NIH, in Mexico, epidemiological data reveals that the prevalence of physician-diagnosed asthma in adults is 3.3% in men and 6.2% in women.
Notably, in children and adolescents, findings from a study by Morales-Romero and colleagues indicate a reported prevalence of 12.7%. Moreover, nonprofit organizations such as the International Community Foundation (ICF) are working toward increasing health, education, and environmental grantmaking to local organizations in Mexico.
Horizon Databook provides a detailed overview of country-level data and insights on the Mexico asthma therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Mexico asthma therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account